Dr Catherine Denning considers PLLA with HA skin boosters for weight-loss side effects
The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity management has transformed weight-loss outcomes for many patients.¹⁻³ While GLP-1 medication can deliver metabolic benefits, rapid weight reduction is also associated with skin laxity, volume loss and accelerated ageing.⁴˒⁵ These changes are increasingly recognised as consequences of alterations in both subcutaneous and dermal adipose tissue compartments.⁵˒⁶
As aesthetic practitioners encounter growing numbers of patients receiving GLP-1 therapies, there is a need for evidence-informed treatment protocols that address the biological consequences of weight-loss-associated facial ageing.⁷⁻⁹
Pathophysiology
In healthy, youthful skin, dermal adipose tissue is characterised by numerous small, metabolically active adipocytes that support adipose-derived stem cell signalling and exert predominately…
